BRAF as a therapeutic target: a patent review (2006 – 2012)

Bibliography

• Wellbrock C, Ogilvie L, Hedley D, V599EB-RAF is an oncogene in melanocytes. Cancer Res 2004;64(7):2338-42
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-54
   PubMed Web of Science ®Google Scholar
• Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004;6(4):313-19
   PubMed Web of Science ®Google Scholar
• Wan PTC, Garnett MJ, Roe SM, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116(6):855-67
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB, Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363(9):809-19
   PubMed Web of Science ®Google Scholar
• Kefford FF, Arkenau H, Brown MP, Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010;28(15s):8503
   Google Scholar
• Chapman PB, Hauschild A, Robert C, Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364(26):2507-16
   PubMed Web of Science ®Google Scholar
• Nagar B, Bornmann WG, Pellicena P, Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002;62(15):4236-43
   PubMed Web of Science ®Google Scholar
• Wada K, Ito M, Fujiwara K, Iwasaki S; inventors; Daiichi Sankyo Co., Ltd, Japan. assignee. Preparation of N,N'-diphenylurea and N-phenyl-N'-pyridylurea derivatives as BRAF kinase inhibitors patent. WO2008044688A1; 2008
   Google Scholar
• Wada K, Iwadare H, Ota M, inventors; Daiichi Sankyo Co., Ltd, Japan. assignee. Preparation of quinazoline derivatives as BRAF kinase inhibitors patent. WO2011068187A1; 2011
   Google Scholar
• Abraham S, Bhagwat S, Campbell BT, inventors; Ambit Biosciences Corp., USA. assignee. Preparation of quinazoline derivatives as RAF kinase modulators for treating cancers, inflammations and immune diseases patent. WO2009117080A1; 2009
   Google Scholar
• Aquila B, Lyne P, Pontz T; inventors; Astrazeneca AB, Swed.; Astrazeneca UK Ltd. assignee. Preparation of B-Raf kinase inhibiting quinazolines as anticancer drugs patent. WO2007113557A1; 2007
   Google Scholar
• Aquila B, Lyne P, Pontz T; inventors; AstraZeneca AB, Swed.; AstraZeneca UK Ltd. assignee. Preparation of substituted phenylaminopyrimidines as B-Raf inhibitors patent. WO2006079791A1; 2006
   Google Scholar
• Aquila B, Dakin L, Ezhuthachan J, inventors; Astrazeneca AB, Swed.; Astrazeneca UK Ltd. assignee. Preparation of substituted quinazolones as B-Raf kinase inhibitors for the treatment of cancer patent. WO2005123696A1; 2005
   Google Scholar
• Niculescu-Duvaz D, Springer CJ, Gill AL, inventors; Cancer Research Technology Ltd, UK; Institute of Cancer Research Royal Cancer Hospital; Astex Therapeutics Ltd. assignee. Preparation of imidazo[4,5-b]pyridin-2-ones and oxazolo[4,5-b]pyridin-2-ones as inhibitors of RAF kinase patent. WO2006043090A1; 2006
   Google Scholar
• Springer C, Niculescu-Duvaz I, Marais R, inventors; Cancer Research Technology Ltd, UK; Institute of Cancer Research Royal Cancer Hospital. assignee. Preparation of 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)phenyl]urea and related compounds as antitumor agents patent. WO2011092469A1; 2011
   Google Scholar
• Springer CJ, Niculescu-Duvaz D, Niculescu-Duvaz I, inventors; Cancer Research Technology Ltd, UK; Institute of Cancer Research Royal Cancer Hospital. assignee. Preparation of pyrido[2,3-b]pyrazine-8-substituted compounds as RAF inhibitors patent. WO2009077766A1; 2009
   Google Scholar
• Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, inventors; Cancer Research Technology Ltd, UK; Royal Cancer Hospital, Institute of Cancer Research. assignee. Preparation of substituted aryl-quinolyl ureas and amides and their use patent. WO2009130487A1; 2009
   Google Scholar
• Springer CJ, Niculescu-Duvaz I, Roman VE, inventors; The Wellcome Trust Ltd, UK. assignee. Preparation of pyrazines and pyridines and derivatives thereof as therapeutic compounds patent. WO2006067466A2; 2006
   Google Scholar
• King AJ, Patrick DR, Batorsky RS, Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res 2006;66(23):11100-5
   Google Scholar
• Pulici M, Marchionni C, Traquandi G, inventors; Nerviano Medical Sciences S.r.l., Italy. assignee. Preparation of N-pyrazolylphenyl benzenesulfonamides as antitumor agents patent. WO2012016993A1; 2012
   Google Scholar
• Pulici M, Zuccotto F, Badari A, inventors; Nerviano Medical Sciences S.r.l., Italy. assignee. Preparation of 3,4-diarylpyrazoles as protein kinase inhibitors patent. WO2010010154A1; 2010
   Google Scholar
• Tang J, Nakano M, Hamajima T; inventors; Smithkline Beecham Corp., USA. assignee. Preparation of 3-[1-ethyl-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]phenyl phenyl ureas for treating conditions mediated by at least one BRaf family kinase patent. WO2007090141A2; 2007
   Google Scholar
• Steurer S, Ettmayer P, Mantoulidis A; inventors; Boehringer Ingelheim International GmbH, Germany. assignee. Preparation of pyridyltriazole derivatives for use as B-Raf kinase inhibitors patent. WO2011117381A1; 2011
   Google Scholar
• Ettmayer P, Steurer S; inventors; Boehringer Ingelheim International GmbH, Germany. assignee. Preparation of pyridyltriazole derivatives for use as B-Raf kinase inhibitors patent. WO2011117382A1; 2011
   Google Scholar
• Herbert MR, Lang H, Gahman TC, inventors; Kalypsys, Inc., USA. assignee. Preparation of thiadiazolyloxyphenylureas as protein kinase inhibitors patent. WO2007076460A2; 2007
   Google Scholar
• Dorr R, Flynn G, Han H, Hurley L; inventors; University of Arizona, USA; Translational Genomics Research Institute. assignee. Compounds, pharmaceutical compositions and methods of use of 2-aryl pyridylazoles patent. WO2010121243A1; 2010
   Google Scholar
• Bollag G, Hirth P, Tsai J, Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010;467(7315):596-9
   PubMed Web of Science ®Google Scholar
• Ibrahim PN, Spevak W, Cho H, inventors; Plexxikon, Inc., USA. assignee. Preparation of substituted phenyl(1H-pyrrolo[2,3-b]pyridin-3-yl)methanones and phenyl(7H-pyrrolo[2,3-d]pyrimidin-5-yl)methanones as protein kinase modulators, particularly inhibitors of Raf protein kinases patent. WO2011063159A1; 2011
   Google Scholar
• Ibrahim PN, Wu G, Lin J, inventors; Plexxikon, Inc., USA. assignee. Preparation of pyrrolopyridine compounds useful for kinase modulation patent. WO2011079133A2; 2011
   Google Scholar
• Hirose M, Okaniwa M, Hayashi Y, Takagi T; inventors; Takeda Pharmaceutical Co., Ltd, Japan. assignee. Preparation of heterocyclic compounds as Raf inhibitors for treatment of cancer patent. WO2009028629A1; 2009
   Google Scholar
• Lang H, Gahman TC, Davis RL, Scranton SA; inventors; Kalypsys, Inc., USA. assignee. Preparation of 2-arylbenzimidazole amide and urea derivatives as inhibitors of B-Raf kinase, and their pharmaceutical compositions and use in the treatment of cancer and other diseases patent. WO2006124780A2; 2006
   Google Scholar
• Okaniwa M; inventor Takeda Pharmaceutical Co., Ltd, Japan. assignee. Preparation of 2-(acylamino)[1,3]thiazolo[5,4-b]pyridine derivatives as Raf kinase inhibitors patent. WO2010064611A1; 2010
   Google Scholar
• Tomita N, Imada T; inventors; Takeda Pharmaceutical Co., Ltd, Japan. assignee. Preparation of indazole and benzisoxazole derivatives as Raf inhibitors for treatment of cancer patent. WO2009028655A1; 2009
   Google Scholar
• Smith CR, Bounaud P-Y, Jefferson EA, inventors; SGX Pharmaceuticals, Inc., USA. assignee. Preparation of triazolopyridazine protein kinase modulators patent. WO2008051805A2; 2008
   Google Scholar
• McKenna J, Papa PW, Sakata ST, inventors; Signal Pharmaceuticals, LLC, USA. assignee. Preparation of thieno[2,3-d]pyrimidines as inhibitors of TNFŒ±, PDE4 and B-raf, their compositions and use patent. WO2007084560A2; 2007
   Google Scholar
• Kienzle NA, Doyle AG, Rowe T; inventors; Cephalon Australia Pty Ltd, Australia. assignee. Antibody for treatment of cancer involving mutated KRAS or BRAF genes patent. WO2011054030A1; 2011
   Google Scholar
• Lavoie H, Sahmi M, Therrien M, inventors; Universite de Montreal, Can.; Mount Sinai Hospital. assignee. RAF homodimers and heterodimers with KSR and their mutants and uses to inhibit dimerization and screen for inhibitors patent. WO2011009218A1; 2011
   Google Scholar
• Adjei A, Drew L, Friday B, inventors; Astrazeneca AB, Swed.; Astrazeneca UK Ltd. assignee. Combination of a MEK inhibitor and a B-raf inhibitor for the treatment of cancer patent. WO2008120004A1; 2008
   Google Scholar
• Auger K, Bachman KE, Greshock JD, inventors; Glaxosmithkline LLC, USA. assignee. Combination of N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide and 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide for treating cancer patent. WO2011046894A1; 2011
   Google Scholar
• Dhingra K, Higgins B, Kolinsky K, inventors; F. Hoffmann-La Roche AG, Switz. assignee. B-raf kinase inhibitor in combination with EGFR inhibitor and topoisomerase inhibitor for treatment of cancer patent. WO2012022724A1; 2012
   Google Scholar
• Gilmer TM, Kumar R, Liu L; inventors; Glaxosmithkline LLC, USA. assignee. Pharmaceutical combination of a vascular endothelial growth factor receptor (VEGFR) inhibitor and a MEK inhibitor useful for treating cancer patent. WO2012027438A1; 2012
   Google Scholar
• Weber B, Wooster RF; inventors; Cytokinetics, Inc., USA. assignee. Novel combinations including a CENP-E inhibitor as cancer treatments patent. WO2011031308A1; 2011
   Google Scholar
• Dhingra K, Higgins B, Kolinsky K, inventors; F. Hoffmann-La Roche AG, Switz. assignee. B-raf kinase inhibitor in combination with topoisomerase inhibitor and EGFR inhibitor for treatment of cancer patent. WO2012022677A2; 2012
   Google Scholar
• Jure-Kunkel M, Wigginton JM, Gupta AK; inventors; Bristol-Myers Squibb Co., USA. assignee. Combination of anti-CTLA4 antibody with Braf-kinase inhibitors for the synergistic treatment of proliferative diseases patent. WO2012027536A1; 2012
   Google Scholar
• Infante JR, Falchook GS, Lawrence DP, Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). ASCO Meet Abstr 2011;29(18_Suppl):CRA8503
   Google Scholar
• Hooijkaas A, Gadiot J, Morrow M, Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. Oncoimmunology 2012;1(5):609-17
   PubMed Web of Science ®Google Scholar
• Koya RC, Mok S, Otte N, BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res 2012;72(16):3928-37
   PubMed Web of Science ®Google Scholar
• Dong J; inventor Mount Sinai School of Medicine of New York University, USA. assignee. Treatment of cancer by simultaneous inhibition of B-RAF and restoration or mimicry of p16 INK4A activity patent. WO2006053201A2; 2006
   Google Scholar
• Polsky D, Osman I, Chapman PB; inventors; New York University School of Medicine, USA; Memorial Sloan-Kettering Cancer Center. assignee. Methods for detecting mutant BRAF gene in circulating melanoma cells using real-time PCR patent. US20060246476A1; 2006
   Google Scholar
• Grebe SKG, Pittelkow MR, Halling KC, inventors; Mayo Foundation for Medical Education and Research, USA. assignee. Methods for detecting mutant B-raf genes in circulating tumor cells and their use in diagnosis patent. US20070020657A1; 2007
   Google Scholar
• Langland R, Sharp T, Will S, Wu L; inventors; Roche Diagnostics GmbH, Germany; F. Hoffmann-La Roche AG. assignee. Methods for detecting mutation in B-Raf gene associated with increased susceptibility to PLX4032 for treatment of melanoma patent. EP2036990A1; 2009
   Google Scholar
• Chen F, Wang T, Qin Y, Wang X; inventors; Suzhou MicroDiag Biomedicine Co., Ltd, Peop. Rep. China. assignee. Detection of BRAF gene mutation by PCR patent. CN101875971A; 2010
   Google Scholar
• Hosomi T, Komori M; inventors; ARKRAY, Inc., Japan. assignee. Diagnostic oligonucleotide probes and primers for detecting polymorphisms in disease-associated genes K-Ras and BRAF patent. WO2011071046A1; 2011
   Google Scholar
• Xu J, Chen Z, Li J; inventors; Beijing ACCB Biotech Ltd, Peop. Rep. China. assignee. Detection of mutation in human BRAF gene using real time PCR for diagnosis of cancers patent. CN102161990A; 2011
   Google Scholar
• Zhang L, Yu H, Song F, inventors; Jiangsu Institute of Nuclear Medicine, Peop. Rep. China. assignee. Method for detecting mutation of BRAF gene in tumor tissue patent. CN102220422A; 2011
   Google Scholar
• Teng L, Jiang W, Fu F, inventors; Zhejiang University, Peop. Rep. China. assignee. Primers and probes used for detecting mutations of gene brafv600e patent. CN102242207A; 2011
   Google Scholar
• Stephens C, Danenberg K; inventors; Response Genetics, Inc., USA. assignee. Methods, primers, probes for detection of BRAF gene mutations associated with metastatic melanoma and diagnostic and therapeutic applications patent. WO2011019704A2; 2011
   Google Scholar
• Hoon DSB; inventor John Wayne Cancer Institute, USA. assignee. Real-time PCR detection of human gene B-RAF V600E mutation for use in diagnosis and treatment of cancer patent. WO2008106453A2; 2008
   Google Scholar
• Lu Y, Britton AE, King TH, inventors; Globeimmune, Inc., USA. assignee. Methods for amplifying and detecting rate mutations in ras, braf and egfr genes associated with cancer and diagnostic and therapeutic applications patent. WO2010065626A1; 2010
   Google Scholar
• Park HK, Choi JJ, Cho MH; inventors; Panagene, Inc., S. Korea. assignee. Detection of mutation of BRAF by real-time PCR using PNA clamping probe for diagnosis of cancers patent. WO2011093606A2; 2011
   Google Scholar
• Morandi L; inventor Gammagenetics Sarl, Switz. assignee. Detection of BRAF V600E mutation by allele specific real time quantitative PCR (AS-qPCR) using locked nucleic acids primers and beacon probes patent. WO2011104694A2; 2011
   Google Scholar
• Chen W; inventor Peop. Rep. China. assignee. One-step detection method and test kit for detecting gene mutation and point mutation v600e in B-RAF gene patent. CN102154480A; 2011
   Google Scholar
• Bemis L, Robinson WA; inventors; University of Colorado, USA. assignee. PCR-based methods and compositions for identifying mutations in cancer-related genes patent. WO2011130636A2; 2011
   Google Scholar
• Wei Q, Wang W, Gao Y, inventors; Shenzhen BGI Science and Technology Co., Ltd, Peop. Rep. China. assignee. PCR and MS for detecting nucleotide mutation sites in KRAS gene and/or BRAF gene patent. CN101838683A; 2010
   Google Scholar
• Xu J, Li G, Yu G, Qin H; inventors; Guangzhou Surexam Bio-Tech Co., Ltd, Peop. Rep. China. assignee. Preparation of liquid chip for detecting BRAF gene mutations for diagnosis of cancer patent. WO2011131146A1; 2011
   Google Scholar
• Von DA, Capper D, Zentgraf H; inventors; Deutsches Krebsforschungszentrum, Germany; Ruprecht-Karls-Univeristaet Heidelberg. assignee. Means and methods for diagnosing cancer using an antibody which specifically binds to BRAF v600e patent. WO2012042009A1; 2012
   Google Scholar
• Capper D, Preusser M, Habel A, Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011;122(1):11-19
   PubMed Web of Science ®Google Scholar
• Sullivan RJ, Flaherty KT. BRAF in melanoma: pathogenesis, diagnosis, inhibition, and resistance. J Skin Cancer 2011;2011:423239
   Google Scholar
• Hatzivassiliou G, Malek S; inventors; Genentech, Inc., USA. assignee. Determining sensitivity of cells to B-Raf inhibitor treatment by detecting K-ras mutation and RTK expression levels patent. WO2011028540A1; 2011
   Google Scholar
• Bleam M, Gilmer TM, Greger JG Jr, inventors; GlaxoSmithKline LLC, USA. assignee. Method of treatment with BRaf inhibitor patent. WO2012068468A1; 2012
   Google Scholar
• Shi H, Moriceau G, Kong X, Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 2012;3:724
   PubMed Web of Science ®Google Scholar
• Shi H, Moriceau G, Kong X, Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov 2012;2:414-24
   PubMed Web of Science ®Google Scholar
• Garraway LA, Emery C, Wagle N; inventors; Dana-Farber Cancer Institute, Inc., USA. assignee. Methods for genotyping MEK1 gene mutation conferring resistance to RAF and MEK inhibitors in treatment of metastatic melanoma patent. WO2011156588A1; 2011
   Google Scholar
• Corcoran RB, Ebi H, Turke AB, EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012;2:227-35
   PubMed Web of Science ®Google Scholar
• Lehrer R, Coopersmith R; inventors; CollabRx, Inc., USA. assignee. Method to treat melanoma in BRAF inhibitor-resistant subjects using multiple receptor tyrosine kinase inhibitors patent. WO2012027716A1; 2012
   Google Scholar
• Prahallad A, Sun C, Huang S, Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012;483(7387):100-3
   PubMed Web of Science ®Google Scholar
• Garraway L, Emery C; inventors; Dana-Farber Cancer Institute, Inc., USA. assignee. BRAF mutations conferring resistance to anticancer BRAF inhibitors and diagnostic and drug screening uses thereof patent. WO2011106298A1; 2011
   Google Scholar
• Lo RS, Ribas A; inventors; University of California, USA. assignee. Methods for detection and treatment of B-RAF inhibitor-resistant melanomas using combination chemotherapy patent. WO2012068562A2; 2012
   Google Scholar
• Ferrone S, Wang X, Favoino E, inventors; University of Pittsburgh, USA. assignee. Synergistic combination of anti-HMW-MAA antibody and BRAF inhibitor for treatment of melanoma or other cancer and metastasis patent. WO2012075324A1; 2012
   Google Scholar
• Ferrone S, Wang X, Favoino E, inventors; University of Pittsburgh, USA. assignee. Methods for treating a tumor using an antibody that specifically binds grp94 patent. WO2012075327A1; 2012
   Google Scholar
• Su F, Viros A, Milagre C, RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366(3):207-15
   PubMed Web of Science ®Google Scholar
• Weber JS, Flaherty KT, Infante JR, Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma. ASCO Meet Abstr 2012;30(15_Suppl):8510
   Google Scholar